Xuanta Pharmaceuticals announced that the company's application for Dapagliflozin and Metformin Hydrochloride Sustained-Release Tablets has been officially approved by the National Medical Products Administration. It is the first generic drug of its kind to be approved domestically. Dapagliflozin and Metformin Hydrochloride Sustained-Release Tablets are used to treat type 2 diabetes. The original research was conducted by AstraZeneca and was approved for market in China in June 2023. It has been included in the Category B payment of medical insurance.
宣泰医药：达格列净二甲双胍缓释片获国家药品监督管理局批准
Xuanta Pharmacy: Dapagliflozin and Metformin Hydrochloride Sustained-Release Tablets Approved by the National Medical Products Administration.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated